Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 7,623 matching trials from the live ClinicalTrials.gov search.
Filters: Jacksonville, Florida Clear all
Terminated No phase listed Observational

Plicated Laparoscopic Adjustable Gastric Banding (Lap Band)

NCT01497028
View directory record Official record
Conditions
Weight Loss
Interventions
PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.
Procedure
Lead sponsor
Jacksonville Surgical Associates
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Ventura, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)

NCT00190736
View directory record Official record
Conditions
ADHD
Interventions
Atomoxetine Hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 54 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
19
States / cities
Lafayette, California • Spring Valley, California • Farmington, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

NCT01979536
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Interventions
Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
154
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 3 Interventional Results available

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

NCT02111564
View directory record Official record
Conditions
Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases, Rheumatic Diseases
Interventions
Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
40 Years and older
Enrollment
12,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
135
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 132 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

NCT01281839
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435, Placebo, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Bakersfield, California • Aurora, Colorado • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma

NCT00667407
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol 1.25 mg, Racemic Albuterol Sulfate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
28
States / cities
Hoover, Alabama • Montgomery, Alabama • Encinitas, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Not applicable Interventional Results available

X-3 Polyethylene Survival Outcomes Study

NCT00493792
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Total Knee Replacement
Interventions
X3 Polyethylene, N2Vac Polyethylene
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 85 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 31, 2026, 6:50 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

NCT02864953
View directory record Official record
Conditions
Brain Edema, Stroke, Acute
Interventions
BIIB093, Placebo
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome

NCT00514501
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Iodofiltic acid I 123
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
40 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 31, 2026, 6:50 AM EDT
Not listed Phase 1Phase 2 Interventional

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

NCT04942067
View directory record Official record
Conditions
Multiple Myeloma, Amyloidosis
Interventions
APG-2575+ Pd, APG-2575 + DRd
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Jacksonville, Florida • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 2 Interventional

Melatonin and Radiation Therapy in Treating Patients With Brain Metastases

NCT00031967
View directory record Official record
Conditions
Metastatic Cancer, Radiation Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
therapeutic melatonin, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
0 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
215
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 1Phase 2 Interventional

Fatty Liver Disease in Obese Children

NCT02117700
View directory record Official record
Conditions
Obesity, Nonalcoholic Fatty Liver Disease, Cardiovascular Disease
Interventions
N-acetyl cysteine 600 mg once/day, N-acetyl cysteine 600mg twice/day, Placebo twice/day
Dietary Supplement · Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 31, 2026, 6:50 AM EDT
Recruiting Phase 1 Interventional

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

NCT06375044
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
SIM0500
Drug
Lead sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • Orange, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors

NCT00088101
View directory record Official record
Conditions
Hematological Malignancies, Leukemia, Lymphoma, Metastatic or Unresectable Solid Tumors
Interventions
STA-5312
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
8
States / cities
Pomona, California • Jacksonville, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics

NCT02360319
View directory record Official record
Conditions
Schizophrenia
Interventions
Any FDA approved antipsychotic agent, aripiprazole long acting injectable formulation
Drug
Lead sponsor
Vanguard Research Group
Other
Eligibility
18 Years to 35 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
39
States / cities
Tucson, Arizona • Granada Hills, California • Palo Alto, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

NCT02048371
View directory record Official record
Conditions
Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcoma, Rhabdomyosarcoma, Mesenchymal Chondrosarcoma
Interventions
Regorafenib, Placebo
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
5 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

NCT03052764
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence
Interventions
onabotulinumtoxinA, Placebo (saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Laguna Hills, California • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1 and 2 Study of PX-866 and Cetuximab

NCT01252628
View directory record Official record
Conditions
Incurable Metastatic Colorectal Carcinoma, Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions
PX-866 (SCCHN), Cetuximab (SCCHN), PX-866 (CRC), Cetuximab (CRC)
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
31
States / cities
Birmingham, Alabama • Escondido, California • Monterey, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 31, 2026, 6:50 AM EDT
Recruiting Phase 1 Interventional

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

NCT05303467
View directory record Official record
Conditions
Glioblastoma Multiforme, Recurrent Glioblastoma
Interventions
TheraSphere GBM
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 6:50 AM EDT
Terminated Phase 2 Interventional Results available

Long-term Safety Study of Brodalumab in Adults With Crohn's Disease

NCT01199302
View directory record Official record
Conditions
Crohn's Disease
Interventions
Brodalumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
11
States / cities
Birmingham, Alabama • Jacksonville, Florida • Hammond, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 2 Interventional

A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

NCT00055419
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Cetuximab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
29
States / cities
Bakersfield, California • Los Angeles, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2010 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01072630
View directory record Official record
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
46
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 31, 2026, 6:50 AM EDT
Completed Not applicable Interventional

Misago® RX Self-expanding Peripheral Stent for Common and/or External Iliac Artery

NCT02793492
View directory record Official record
Conditions
Iliac Artery Stenosis
Interventions
Misago® RX Self-expanding Peripheral Stent
Device
Lead sponsor
Terumo Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Thornton, Colorado • Gainesville, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 31, 2026, 6:50 AM EDT
Terminated Not applicable Interventional

Ultrasound Image Fusion for Placement of Sacral Quadripolar Leads

NCT01054534
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Placement of interstim lead
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 90 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 31, 2026, 6:50 AM EDT